Active	Status	Sponsor type	Region	Phase	Filter
8 Active 3 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ding, Xueying
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration	Active, not recruiting	3	488	RoW	TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis	TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Neovascular Age-related Macular Degeneration	09/24	02/25
NCT06270030: Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia	Completed	1	21	RoW	LNZ101 (Aceclidine /Brimonidine) ophthalmic solution, LNZ100 (Aceclidine) ophthalmic solution, Placebo (Vehicle) ophthalmic solution	Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., LENZ Therapeutics, Inc	Presbyopia	04/24	04/24
NCT06604949: A Study of Single Dose of LP-003 in Healthy Adult Subjects	Not yet recruiting	1	12	RoW	LP-003 200mg, Placebo	Longbio Pharma, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Chronic Spontaneous Urticaria	11/26	12/26
NCT06023095: A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities	Completed	1	24	RoW	LY3502970, Placebo	Eli Lilly and Company	Overweight, Obesity	07/24	07/24
NCT06674525: Evaluation of 626 in Healthy Adult Subjects	Recruiting	1	50	RoW	626, SSGJ-626, Placebo	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Healthy Subjects (HS)	06/25	10/25